Myriad Genetics Inc

19 de ago. de 2026, 20:02 UTC

Myriad Genetics shares are trading higher, rebounding from pre-market losses amid strong buying interest during the session. The stock remains near its one-month low.

18 de ago. de 2026, 20:03 UTC

Myriad Genetics shares are trading lower amid an investigation and revised revenue guidance of $770-$790 million, down from $860-$880 million.

17 de ago. de 2026, 19:26 UTC

Myriad Genetics Inc. shares are higher today, reaching a peak late in the session, though they remain below their 20-day moving average.

14 de ago. de 2026, 19:46 UTC

Myriad Genetics Inc. shares are lower amid an investigation by Bronstein, Gewirtz & Grossman, LLC, and disappointing Q2 results with revised revenue guidance.

13 de ago. de 2026, 19:41 UTC

Myriad Genetics shares are lower as the company faces an investigation and lowers its full-year revenue guidance to $770-$790 million.

12 de ago. de 2026, 19:31 UTC

Myriad Genetics Inc shares are lower as the company faces an investigation and reports declining Q2 revenue of $190.7 million, missing expectations.

11 de ago. de 2026, 20:06 UTC

Myriad Genetics Inc shares are lower amid a securities investigation and disappointing Q2 results, which included a revenue decline and lowered full-year guidance.

7 de ago. de 2026, 19:51 UTC

Myriad Genetics shares are higher today, driven by a broader advance in biotechnology stocks. The move breaks from a recent pattern of higher daily closes.

6 de ago. de 2026, 20:03 UTC

Shares of Myriad Genetics are trading higher today, despite fluctuations during the session. The overall trend remains positive since Wednesday's close.

5 de ago. de 2026, 21:21 UTC

Myriad Genetics Inc shares are higher in after-market hours, reflecting broader market gains amid positive technology stock performance and favorable economic data.

4 de ago. de 2026, 20:04 UTC

Myriad Genetics shares are higher today, supported by overall market gains and positive sentiment amid declining crude oil prices and comments on potential peace talks with Iran.

3 de ago. de 2026, 20:03 UTC

Myriad Genetics gains amid broader market strength, tightening revenue guidance to $770 million to $790 million while facing reimbursement challenges. Shares remain higher since Friday.

31 de jul. de 2026, 23:11 UTC

Myriad Genetics Inc shares are higher in after-market hours, recovering from earlier lows. The stock remains below its 20-day moving average.

30 de jul. de 2026, 22:51 UTC

Myriad Genetics shares fell in after-market trading following disappointing Q2 results, with revenue of $190.7 million missing expectations and a revised revenue outlook.

29 de jul. de 2026, 18:07 UTC

Myriad Genetics Inc. shares are lower today, continuing a four-session decline amid broader market concerns over rising crude oil prices and inflation worries.

28 de jul. de 2026, 18:06 UTC

Myriad Genetics faces negative sentiment after being labeled unprofitable. Shares are lower today, continuing a trend of declines over the past three sessions.

27 de jul. de 2026, 18:16 UTC

Myriad Genetics shares are lower amid a broader market trend and significant declines in crude oil prices, despite earlier session volatility.

24 de jul. de 2026, 19:36 UTC

Myriad Genetics shares are lower amid scrutiny over financial performance and stagnant revenue growth, reflecting ongoing challenges in the broader market.

22 de jul. de 2026, 20:06 UTC

Myriad Genetics Inc shares are lower today, continuing a decline from Tuesday's close amid mixed sentiment ahead of the Federal Reserve meeting.

20 de jul. de 2026, 18:22 UTC

Myriad Genetics Inc. shares are lower today, continuing a recent decline amid rising U.S. Treasury yields and inflation concerns tied to increasing oil prices.